Novacyt S.A. (NCYT.L) Research

Novacyt S.A., together with its associated entities, specializes in the research, production, contract design, and market launch of diagnostic solutions. These offerings are primarily developed for the detection of cancer and a range of infectious diseases. The company maintains an extensive international operational footprint, encompassing the United Kingdom, the broader European continent, the United States, the Asia Pacific region, the Middle East, and Africa. Its operations are segmented into three core divisions: Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment is dedicated to the conceptualization, manufacturing, and commercialization of molecular real-time qPCR testing equipment and corresponding reagents, specifically for infectious disease diagnostics. The Lab21 Products division focuses on the development, production, and supply of various protein-based in-vitro diagnostic (IVD) devices that target infectious illnesses. Meanwhile, IT-IS International is responsible for engineering and fabricating PCR devices utilized within both the life sciences and food testing industries. Novacyt serves a diverse client base, including healthcare institutions and corporate organizations. The company was established in 2006 and is headquartered in Vélizy-Villacoublay, France.

Open Novacyt S.A. (NCYT.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.